Llwytho...
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
This phase I dose-escalation/expansion study evaluated isatuximab (anti-CD38 monoclonal antibody) monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). Patients progressing on or after standard therapy received intravenous isatuximab (weekly [QW] or every 2 weeks [Q2W]). The prim...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Blood Cancer J |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Publishing Group UK
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6440961/ https://ncbi.nlm.nih.gov/pubmed/30926770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0198-4 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|